ABT - Abbott Laboratories
NEXT EARNINGS:
Apr 15, 2026
EPS Est: $1.15
|
Rev Est: $11.0B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$134.64
DETAILS
HIGH:
$152.00
LOW:
$120.00
MEDIAN:
$135.00
CONSENSUS:
$134.64
UPSIDE:
17.51%
Market Cap:
199.42B
Volume:
9,001,232
Avg Volume:
8,941,880
52 Week Range:
105.27-141.23
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
0.75
Last Dividend:
$2.40
Exchange:
NYSE
Country:
US
Employees:
114,000
IPO Date:
1980-03-17
EPS (TTM):
3.74
P/E Ratio:
33.55
Revenue (TTM):
44.33B
Total Assets:
86.71B
Total Debt:
15.07B
Cash & Equiv:
8.52B
Rev Growth (5Y):
5.1%
EPS Growth (5Y):
8.2%
FCF Growth (5Y):
5.3%
ROCE:
12.2%
Debt/Equity:
0.29
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-22 | $1.50 | $1.50 | 0.0% | $11.5B | $11.8B | -2.9% |
| 2025-10-15 | $1.30 | $1.30 | 0.0% | $11.4B | $11.4B | -0.2% |
| 2025-07-17 | $1.26 | $1.26 | 0.0% | $11.1B | $11.1B | +0.5% |
| 2025-04-16 | $1.09 | $1.07 | +1.9% | $10.4B | $10.4B | -0.5% |
| 2025-01-22 | $1.34 | $1.34 | 0.0% | $11.0B | $11.0B | -0.5% |
| 2024-10-16 | $1.21 | $1.20 | +0.8% | $10.6B | $10.6B | +0.8% |
| 2024-07-18 | $1.14 | $1.10 | +3.6% | $10.4B | $10.4B | 0.0% |
| 2024-04-17 | $0.98 | $0.95 | +2.6% | $10.0B | $9.9B | +0.8% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B |
| Net Income | 6.52B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B |
| EPS | 3.74 | 7.67 | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 |
| Total Assets | 86.71B | 81.41B | 73.21B | 74.44B | 75.20B | 72.55B | 67.89B | 67.17B | 76.25B | 55.01B | 44.00B | 43.79B |
| Total Debt | 15.07B | 15.28B | 15.87B | 17.95B | 19.25B | 19.89B | 19.10B | 19.57B | 27.92B | 22.01B | 9.00B | 7.83B |
| Cash & Equivalents | 8.52B | 7.62B | 6.90B | 9.88B | 9.80B | 6.84B | 3.86B | 3.84B | 9.41B | 18.62B | 5.00B | 4.06B |
| Operating Cash Flow | 9.57B | 8.56B | 7.26B | 9.58B | 10.53B | 7.90B | 6.14B | 6.30B | 5.57B | 3.20B | 2.97B | 3.67B |
| Free Cash Flow | 7.39B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B | 4.50B | 4.91B | 4.43B | 2.08B | 1.86B | 2.60B |
| FCF per Share | 4.23 | 3.67 | 2.92 | 4.45 | 4.87 | 3.23 | 2.54 | 2.79 | 2.54 | 1.41 | 1.26 | 1.72 |
| Book Value | 52.13B | 47.66B | 38.60B | 36.69B | 35.80B | 32.78B | 31.09B | 30.52B | 30.90B | 20.54B | 21.21B | 21.53B |
| Cash & ST Investments | 8.94B | 7.97B | 7.28B | 10.17B | 10.25B | 7.15B | 4.14B | 4.09B | 9.61B | 18.77B | 6.12B | 4.46B |
| ROC Equity | 0.13 | 0.28 | 0.15 | 0.19 | 0.20 | 0.14 | 0.12 | 0.08 | 0.02 | 0.07 | 0.21 | 0.11 |